Magnesium Supplement UK Statistics 2026: Market and Trends

Magnesium supplements have moved from the pharmacy shelf to the cultural conversation. Search interest, social media discussion, and retail sales data all point in the same direction: the UK public is paying more attention to this mineral than at any point in recent memory, and the numbers behind that shift are more substantial than most wellness trends. This page compiles verified UK magnesium statistics drawn from official surveys, regulatory bodies, and named market research firms. Updated July 2026.

This article was written by Clemmie Rose, a registered Nutritional Therapist holding a Diploma in Nutritional Therapy from the College of Naturopathic Medicine, with clinical practice that has included the Wellness Clinic at Harrods. Statistics below are sourced from official UK government survey data (NDNS), the NHS, the European Food Safety Authority (EFSA), and named market research firms. Where data is estimated or paywalled, this is stated explicitly.

The UK magnesium supplement market was valued at USD 161.24 million in 2024, according to market research firm Deep Market Insights. The same analysis projects growth to USD 273.81 million by 2033, a compound annual growth rate of 6.06%. In GBP terms, the 2024 figure equates to approximately £127 million at typical exchange rates.

For context, the global magnesium supplement market was valued at approximately USD 3.5 billion in 2024 (Verified Market Reports, 2024), growing at 6.1% annually. The UK accounts for roughly 5% of that global total and is identified as the fastest-growing market in Europe, ahead of Germany, France, and Italy in the forecast period.

That CAGR of 6% sits above the broader UK food supplement market's average growth rate. This reflects category-specific demand pull rather than general wellness spending.

Deep Market Insights identifies three primary demand signals in the UK market: sleep quality, muscle function, and stress management. Sleep support alone accounted for USD 61 million of UK market value in 2025 - the single largest application category. Tablets remain the dominant delivery format at USD 61.16 million, though powder and functional beverage formats are growing faster.

These market figures come from commercial research firms working from sales data and consumer surveys. They are estimates with inherent methodology variation: different firms use different scopes, which is why headline valuations for the same market category can diverge between reports. The figures from Deep Market Insights and Verified Market Reports cited here are the most UK-specific available in the public domain.

The phrase "magnesium deficiency" circulates widely in wellness media, often implying that most British adults are clinically deficient. The data from official UK survey sources tells a more specific story.

The National Diet and Nutrition Survey (NDNS) is the UK government's primary ongoing dietary intake programme. A secondary analysis of NDNS rolling programme data published in the peer-reviewed literature (PMC6060686, 2018) provides the most granular published breakdown by age and sex for British adults in the working-age population:

• Men aged 20-59: 14.2% have magnesium intakes below the Lower Reference Nutrient Intake (LRNI)
• Women aged 20-59: 11.5% have intakes below the LRNI
• Men aged 20-29: 18.5% below the LRNI - the highest rate across all adult age groups
• Women aged 20-59 as a whole: consume magnesium at approximately 80% of the Reference Nutrient Intake (RNI), compared with 91% for men

The situation is considerably worse among teenagers. The Health Supplements Information Service (HSIS), citing NDNS data, reported in 2020 that nearly 50% of teenage girls and 28% of teenage boys consume below the LRNI for magnesium (HSIS, 2020).

Falling below the LRNI does not mean clinical hypomagnesaemia (serum magnesium below 0.7 mmol/L). The LRNI is the intake level below which deficiency is considered highly probable - it is a threshold for risk, not a clinical diagnosis. Clinical hypomagnesaemia in otherwise healthy adults is comparatively uncommon and is most frequently associated with specific conditions: chronic bowel disease, type 2 diabetes, prolonged alcohol use, or certain medications including diuretics and proton pump inhibitors (Lab Tests Online UK).

The honest read: a meaningful share of UK adults - particularly younger women and men in their twenties - have dietary intakes that fall short of recommended levels. This is not the same as being clinically deficient, but it is a legitimate public health concern for groups with elevated requirements.

The NHS advises that most people can obtain sufficient magnesium from diet. Spinach, nuts, and wholemeal bread are among the dietary sources cited (NHS, 2023). Supplementation is recommended clinically in specific cases, not as a universal population intervention.

The UK magnesium supplement market is not uniform. Different magnesium salts carry different absorption profiles and consumer propositions, and the format mix is shifting.

Magnesium oxide remains the largest format by value in 2025 (USD 52.16 million in the UK, Deep Market Insights), primarily because of its low production cost and long pharmacy-shelf presence. Its bioavailability is estimated at approximately 4% elemental magnesium absorbed per dose.

Magnesium glycinate (also marketed as bisglycinate) is the fastest-growing UK format. The demand driver is dual: superior bioavailability and a gentler gastrointestinal profile compared with oxide forms. Glycinate is the format most associated with sleep and relaxation positioning, which aligns with sleep support being the market's largest application category.

Magnesium citrate is the second highest-growth format, with bioavailability estimated at 25-30% and a strong track record in clinical use. For the clinical absorption comparison between formats, our guide to magnesium glycinate vs malate covers the evidence in detail.

The shift from oxide to chelated forms - glycinate and citrate - reflects consumers reading labels more carefully and prioritising elemental dose over headline milligrams. Magnesium glycinate popularity has been particularly visible at mainstream UK retailers, with Holland and Barrett and MyProtein both expanding glycinate-specific lines in the 2023-2025 period.

The growth in UK magnesium supplement sales is not primarily driven by clinical deficiency messaging. It is driven by three overlapping demand themes.

Sleep is the clearest single signal. A 2024 study published in PubMed (PMID 39910836) found dietary magnesium intake was associated with self-reported short sleep duration. The proposed mechanisms involve magnesium's role in regulating GABA receptor activity and melatonin pathways. The existing evidence is predominantly associative rather than establishing clear causation at population level, but it has been sufficient to establish sleep as the primary consumer motivation for magnesium supplementation in the UK. For product guidance on this use case, our guide to the best magnesium supplements UK covers the evidence and leading formats.

Stress and muscle function are the secondary demand drivers. EFSA-authorised health claims support both. Magnesium is permitted to carry claims for "contribution to a reduction of tiredness and fatigue", "normal muscle function", and "normal energy-yielding metabolism" across the EU and UK markets (EFSA, 2009 and 2010). These are substantiated claims, not marketing assertions. They are not the same as claims about anxiety reduction or cortisol management, which are not EFSA-authorised.

The premium wellness shift is structural. UK consumers are spending more on health and wellness products, and mineral supplements have benefited from the same tailwind as protein powders and adaptogens. The consumer move from oxide toward glycinate and citrate formats is raising average price points and positioning the category differently from the commodity pharmacy aisle.

Source: EFSA Scientific Opinions 2009 (ID 238-365) and 2010 (ID 244-246, 344).

What the evidence does not yet firmly support at population level: magnesium supplementation as a primary treatment for anxiety, clinical insomnia in people without established dietary inadequacy, or elevated cortisol. Research is active and some findings are promising, particularly for subpopulations with low dietary intake. But these are not EFSA-authorised claims, and marketing that presents them as settled should be read carefully.

The NIH Office of Dietary Supplements' review of magnesium and blood pressure finds that supplementation is associated with modest reductions in systolic and diastolic blood pressure, but acknowledges that evidence quality and effect sizes are mixed (NIH ODS Magnesium Health Professional Fact Sheet). Magnesium for sleep demand in the consumer market is outpacing the formal evidence base - a gap worth naming.

The UK magnesium supplement market is positioned for continued above-market growth through the forecast period. Sleep concerns remain one of the most searched health topics in the UK. Stress-related supplement demand among working-age adults remains elevated. The consumer shift from oxide toward magnesium market size UK premium chelated forms is still mid-cycle.

The format transition will continue to push average price points upward. Powder and functional beverage formats are growing faster than tablets and capsules. Two areas to watch: the regulatory environment around specific sleep-related claims, and emerging research into magnesium's role in cognitive health and menopause support - both areas with active clinical investigation and rising consumer interest.

For a current product-by-product breakdown, our guide to the best magnesium complex supplements covers the leading UK options with dose verification.

This page aggregates statistics from four source types.

Market data comes from commercial market research firms (Deep Market Insights, Verified Market Reports) using sales data, retailer surveys, and demand modelling. These are estimates, not official government statistics. Different firms use different scopes and methodologies; headline valuations can vary across reports as a result. Each figure is cited with the specific firm and report URL so readers can verify methodology directly.

Dietary intake data comes from the National Diet and Nutrition Survey (NDNS) rolling programme, accessed via peer-reviewed secondary analyses (PMC6060686, 2018) and the Health Supplements Information Service (HSIS) briefing document (2020), which cites NDNS directly. The NDNS is conducted by UKHSA and the Food Standards Agency and is the authoritative source on UK dietary intakes.

Regulatory and clinical guidance comes from the NHS, EFSA Scientific Opinions on magnesium health claims (2009, 2010), and NIH ODS Magnesium Health Professional Fact Sheet. These are cited for their regulatory status, not as substitutes for clinical advice.

Data gaps: No UK-specific magnesium supplement volume data broken down by format is available from official government sources - format share figures come from commercial market research. NDNS Years 12-15 (2019-2023) magnesium-specific results are not yet published in accessible form; the most recent granular NDNS magnesium analysis is the rolling programme Years 1-9 secondary analysis (PMC6060686, 2018). Any pre-2020 market data is noted as potentially dated.

Last updated: July 2026. This page is reviewed and updated annually.